Raymond James Financial
BIO icon

Raymond James Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

Raymond James Financial’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
37,558
+1,664
+5% +$472K ﹤0.01% 2070
2026
Q1 		$10M Buy
35,894
+2,788
+8% +$803K ﹤0.01% 2023
2025
Q4 		$10M Buy
33,106
+5,867
+22% +$1.83M ﹤0.01% 1960
2025
Q3 		$7.64M Buy
27,239
+4,665
+21% +$1.27M ﹤0.01% 2133
2025
Q2 		$5.45M Buy
22,574
+7,402
+49% +$1.75M ﹤0.01% 2324
2025
Q1 		$3.7M Sell
15,172
-409
-3% -$123K ﹤0.01% 2527
2024
Q4 		$5.12M Buy
+15,581
New +$5.29M ﹤0.01% 2321

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Raymond James Financial's BIO Position: Q2 2026 in Review

Raymond James Financial increased its Bio-Rad Laboratories Class A (BIO) stake by 4.6% in Q2 2026, buying an estimated $472K and bringing the position to 37,558 shares worth $11M. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Raymond James Financial first reported a position in BIO in Q4 2024 and has held it in 7 quarters since. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Raymond James Financial held 37,558 shares of Bio-Rad Laboratories Class A worth $11M as of Q2 2026.
  • Raymond James Financial bought 1,664 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $472K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2070 holding.
  • Raymond James Financial first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and has held it in 7 quarters since.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.